Intra-Cellular Therapies Inc. (ITCI) Financial Statements (2024 and earlier)

Company Profile

Business Address 430 EAST 29TH STREET
NEW YORK, NY 10016
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
MRQ
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments591,905412,33360,046107,63754,948464,331
Cash and cash equivalents148,61592,36560,046107,63754,94837,790
Short-term investments443,290319,968   426,541
Restricted cash and investments1,7501,4001,400   
Receivables75,18920,15610,765   
Inventory, net of allowances, customer advances and progress billings23,9207,9487,056   
Inventory23,9207,9487,056   
Prepaid expense     2,400 
Other undisclosed current assets45,19325,443611,638122,687298,0914,884
Total current assets:737,957467,281690,904230,324355,439469,215
Noncurrent Assets
Operating lease, right-of-use asset14,82420,76424,32518,252
Property, plant and equipment1,9131,7911,9982,2601,1601,137
Other noncurrent assets868686867976
Deferred tax assets, net5291,058
Other undisclosed noncurrent assets    265  
Total noncurrent assets:16,82322,64126,40920,8631,7682,271
TOTAL ASSETS:754,780489,922717,314251,186357,206471,487
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities33,39129,58820,40922,69816,2547,785
Employee-related liabilities20,89714,90715,2732,2931,612
Accounts payable10,3958,6915,5027,42513,9616,174
Accrued liabilities22,996     
Debt    3,187  
Other undisclosed current liabilities49,84523,76816,44410,33920,0456,424
Total current liabilities:83,23653,35636,85336,22436,29914,210
Noncurrent Liabilities
Long-term debt and lease obligation:  18,67523,60019,955  
Liabilities, other than long-term debt15,474   3,1922,840
Deferred revenue and credits2,840
Deferred rent credit     3,192
Operating lease, liability15,47418,67523,60019,955
Other undisclosed noncurrent liabilities  (18,675)(23,600)   
Total noncurrent liabilities:15,47418,67523,60019,9553,1922,840
Total liabilities:98,71072,03160,45456,17939,49217,050
Equity
Equity, attributable to parent656,070417,891656,860195,007317,715454,437
Common stock988655
Additional paid in capital2,137,7371,639,4761,593,476904,972880,753862,480
Accumulated other comprehensive income (loss)(4,190)(364)481128(668)(799)
Accumulated deficit(1,477,486)(1,221,230)(937,104)(710,098)(562,376)(407,249)
Total equity:656,070417,891656,860195,007317,715454,437
TOTAL LIABILITIES AND EQUITY:754,780489,922717,314251,186357,206471,487

Income Statement (P&L) ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Revenues250,31483,80322,81361 246
Revenue, net246
Gross profit:250,31483,80322,81361 246
Operating expenses(513,940)(369,491)(254,041)(154,072)(162,267)(103,086)
Operating loss:(263,626)(285,688)(231,228)(154,012)(162,267)(102,840)
Nonoperating income
(Investment Income, Nonoperating)
7,3761,5684,2356,2917,1414,006
Loss from continuing operations before income taxes:(256,250)(284,120)(226,992)(147,721)(155,126)(98,834)
Income tax expense (benefit)(6)(6)(14)(2)(2)1,061
Loss from continuing operations:(256,256)(284,126)(227,006)(147,722)(155,127)(97,773)
Loss before gain (loss) on sale of properties:(284,126)(227,006)(147,722)(155,127)(97,773)
Net loss available to common stockholders, diluted:(256,256)(284,126)(227,006)(147,722)(155,127)(97,773)

Comprehensive Income ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net loss:(256,256)(284,126)(227,006)(147,722)(155,127)(97,773)
Other comprehensive income (loss)(3,826)(844)352796131(482)
Comprehensive loss, net of tax, attributable to parent:(260,082)(284,970)(226,653)(146,926)(154,996)(98,255)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: